TESAMORELIN · 2 MG | Reduce la Grasa. Mejora tu Metabolismo.

Key Benefits of Tesamorelin Selective Visceral Fat Reduction Tesamorelin acts specifically on visceral and hepatic adipose tissue, stimulating lipolysis in these metabolically active regions . Visceral fat is the most dangerous type of fat for health, as it surrounds internal organs and is strongly associated with cardiovascular disease, metabolic syndrome, and insulin resistance . Phase III clinical studies have demonstrated that Tesamorelin significantly reduces visceral fat compared to placebo, with a mean reduction of approximately 15-20% after 26 weeks of treatment . This selective reduction is crucial, as visceral fat responds differently than subcutaneous fat to dietary and exercise interventions. Lipolysis Stimulation and Fat Mobilization Tesamorelin stimulates the breakdown of stored triglycerides in visceral adipocytes through activation of hormone-sensitive lipase (HSL), the enzyme responsible for fatty acid mobilization . This process releases free fatty acids into the bloodstream, where they are transported to peripheral tissues to be oxidized as an energy source . Lipolysis stimulation is specific to visceral adipose tissue, resulting in focused abdominal fat reduction. Increase in Lean Body Mass Clinical studies have demonstrated that Tesamorelin not only reduces fat but also significantly increases lean body mass (muscle) compared to placebo . This effect is especially valuable during definition and fat loss periods, where the goal is to preserve and even increase muscle tissue while reducing fat. The increase in lean muscle mass contributes to a more active metabolism and better overall body composition. Improved Muscle Density and Reduced Myosteatosis Tesamorelin has been shown to improve muscle density and reduce fat infiltration into muscle tissue (myosteatosis) . Fat infiltration into muscle is associated with decreased muscle function and strength, as well as increased risk of falls and disability in older populations . Myosteatosis reduction contributes to better muscle quality, greater strength, and improved physical performance. Physiological Mechanism and Improved Safety Unlike direct exogenous GH administration, Tesamorelin stimulates pulsatile endogenous GH release from the pituitary gland, mimicking the body&amp;amp;amp;#039;s natural rhythm . This mechanism significantly reduces the risk of side effects associated with exogenous GH, such as insulin resistance, fluid retention, internal organ hypertrophy, and hypothalamic-pituitary axis suppression . Tesamorelin&amp;amp;amp;#039;s safety profile is favorable, with side effects generally mild and transient. Improved Lipid Profile and Reduced Systemic Inflammation Tesamorelin-induced visceral fat reduction is accompanied by significant improvement in lipid profile, including triglyceride reduction and HDL cholesterol increase . Additionally, reduction in systemic inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) has been observed . Systemic inflammation reduction contributes to better overall cardiovascular and metabolic health. Support for Insulin Sensitivity and Glucose Regulation Visceral fat reduction is closely associated with improved insulin sensitivity and glucose regulation . Tesamorelin, by selectively reducing visceral fat, contributes to improved glycemic profile and reduced risk of insulin resistance and type 2 diabetes. Improved Stability and Greater Potency Tesamorelin&amp;amp;amp;#039;s structure includes a chemical modification with trans-3-hexenoic acid at its N-terminus that protects the molecule from enzymatic degradation . This modification extends its half-life and makes it significantly more potent and stable than other GHRH analogs such as Sermorelin . This means Tesamorelin can achieve superior effects with lower doses and less frequent administration.

Function and Mechanism of Action of Tesamorelin Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), composed of 44 amino acids with a chemical modification at its N-terminus . This modification consists of the addition of trans-3-hexenoic acid, which protects the molecule from enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), extending its half-life and increasing its potency compared to other GHRH analogs such as Sermorelin . Detailed Mechanism of Action: Stimulation of Endogenous GH Release: Tesamorelin binds to the GHRH receptor on the pituitary gland, activating the cAMP/PKA signaling pathway that stimulates synthesis and release of endogenous growth hormone (GH) . This release occurs in natural pulses, mimicking the body&amp;amp;amp;#039;s physiological rhythm and maintaining hypothalamic-pituitary axis integrity . The released GH acts on peripheral tissues to stimulate IGF-1 and other growth factor production. Focused Action on Visceral Fat: Tesamorelin, through the endogenous GH it stimulates, exerts a specific lipolytic effect on visceral and hepatic adipose tissue . Activation of hormone-sensitive lipase (HSL) in visceral adipocytes triggers the breakdown of stored triglycerides into free fatty acids and glycerol . This action is selective for visceral fat, unlike other agents that reduce fat broadly without distinction. Increase in Lean Muscle Mass: GH stimulated by Tesamorelin promotes muscle protein synthesis and satellite cell differentiation, resulting in increased lean muscle mass . Additionally, GH improves fatty acid utilization as an energy source, preserving muscle glycogen and structural proteins. Improved Muscle Density and Reduced Myosteatosis: Tesamorelin has been shown to improve muscle density and reduce fat infiltration into muscle tissue (myosteatosis) . This effect is attributed to GH&amp;amp;amp;#039;s ability to stimulate fatty acid oxidation in muscle and reduce intramuscular lipid accumulation. Modulation of Lipid and Glycemic Metabolism: Tesamorelin-induced visceral fat reduction is accompanied by improved lipid profile and insulin sensitivity . GH stimulated by Tesamorelin also promotes fatty acid oxidation in the liver and reduces hepatic steatosis (fatty liver). Comparison with Sermorelin: Tesamorelin differs from Sermorelin in its improved stability and greater potency due to trans-3-hexenoic acid modification . While Sermorelin has a short half-life (approximately 10-15 minutes), Tesamorelin has a significantly longer half-life, allowing less frequent administration and more sustained effects . Additionally, Tesamorelin has been shown to be more effective in visceral fat reduction in Phase III clinical studies.

How to Use Tesamorelin Route of Administration: Injectable via subcutaneous (SC). Subcutaneous administration is the standard method for Tesamorelin, allowing gradual and constant absorption. Injection sites should be rotated (abdomen, thigh, gluteal region) to avoid local irritation and ensure uniform absorption. Reconstitution: The product is presented as a lyophilized powder in a sterile vial. It must be reconstituted with bacteriostatic water for injection (or sterile water for injection) before use. Add the diluent slowly, gently swirling the vial to dissolve the powder. Do not shake vigorously to avoid peptide degradation. Research Protocol: Dosage and frequency must be determined by the researcher according to protocol goals. Common research protocols for Tesamorelin use: Dose: 1-2 mg per administration, 1 time daily . Frequency: Daily administration for 8-16 weeks to achieve desired results . Timing of Administration: Ideally administered at night before bedtime, to take advantage of the natural GH release peak during sleep. Storage: The lyophilized powder should be stored in a cool, dry place, protected from light and at controlled temperature (2-8°C). Once reconstituted, it must be refrigerated (2-8°C) and used within 30 days. Important Notice: Product intended EXCLUSIVELY FOR SCIENTIFIC RESEARCH in vitro and in animal models. Tesamorelin is not FDA-approved for any human use and is classified as an investigational compound . Reported side effects are generally mild and include redness at the injection site, mild arthralgias, and in rare cases, headache or dizziness. Its use carries risks and the researcher is solely responsible for safety and compliance with applicable regulations during protocol development.

Ingredients of Tesamorelin Active Ingredient: Tesamorelin (Tesamorelin Acetate): A synthetic analog of growth hormone-releasing hormone (GHRH) composed of 44 amino acids with a chemical modification at its N-terminus (trans-3-hexenoic acid) that protects the molecule from enzymatic degradation . Modified sequence. Acts by stimulating pulsatile endogenous GH release to reduce visceral fat and improve body composition. The active ingredient purity is ≥99% by HPLC-MS. Excipients: Mannitol: A sugar alcohol that acts as a cryoprotectant and bulking agent, used to stabilize the peptide structure during the lyophilization process. Water for Injection (WfI): High-purity water (USP/EP grade) used as a vehicle in the lyophilization process. Note for Researchers: This product is a high-purity synthetic peptide (&amp;amp;amp;gt;99% by HPLC-MS), manufactured without unnecessary additives, preservatives, or fillers. Its production is carried out under strict quality control standards (GMP). Tesamorelin is not FDA-approved for human use and is intended exclusively for in vitro and animal model scientific research.

Onset Time &amp;amp;amp;amp; Expected Results of Tesamorelin Onset of Action (Days to Weeks): Tesamorelin begins acting within the first hours after administration, stimulating pulsatile GH release from the pituitary gland . Effects on lipolysis and fat mobilization begin to manifest within the first days of treatment, although visible changes in body composition require consistent use. Measurable Benefits (4-8 Weeks): The first measurable changes in body composition, including waist circumference reduction and improvement in muscle definition, begin to be visible within the first 4-8 weeks of consistent use according to the research protocol . Clinical studies have demonstrated that visceral fat reduction is detectable from 8 weeks of treatment. Full Effect (12-16 Weeks): For maximum visceral fat reduction and complete body composition improvement, the full effect often requires 12-16 weeks of consistent use according to the research protocol . Phase III clinical studies have demonstrated that mean visceral fat reduction reaches approximately 15-20% after 26 weeks of treatment. Factors Influencing Results: The speed and magnitude of results depend on dose administered, administration frequency, adherence to the research protocol, nutrition quality, caloric deficit, training type, and individual metabolism.

Clinical Research &amp;amp;amp;amp; 3rd Party Test Results of Tesamorelin Scientific evidence on Tesamorelin comes from Phase II and III clinical studies, as well as preclinical studies in animal models. Research has demonstrated its efficacy in visceral fat reduction, body composition improvement, and systemic inflammation reduction. Clinical Evidence in Humans: Visceral Fat Reduction Studies: A Phase III multicenter, double-blind, placebo-controlled study of 412 patients with abdominal obesity demonstrated that Tesamorelin (2 mg/day) significantly reduced visceral fat compared to placebo after 26 weeks (mean reduction of 15-20%) . Visceral fat reduction was maintained during the treatment period and partially reversed after treatment discontinuation. Body Composition Studies: Clinical studies have demonstrated that Tesamorelin not only reduces visceral fat but also significantly increases lean body mass compared to placebo . In a 26-week study, patients treated with Tesamorelin showed an increase in lean body mass of approximately 1.5 kg compared to placebo. Muscle Density and Myosteatosis Studies: Tesamorelin has been shown to improve muscle density and reduce fat infiltration into muscle tissue (myosteatosis) in computed tomography (CT) studies . Myosteatosis reduction was associated with improved muscle function and strength. Lipid Profile and Inflammation Studies: Clinical studies have demonstrated that Tesamorelin reduces triglycerides, increases HDL cholesterol, and reduces systemic inflammatory markers such as CRP and IL-6 . These effects contribute to better cardiovascular and metabolic health. Safety Studies: Tesamorelin&amp;amp;amp;#039;s safety profile is favorable, with side effects generally mild and transient, including injection site redness, mild arthralgias, and in rare cases, headache or dizziness . No significant increase in insulin resistance or hyperglycemia has been observed in clinical studies. Regulatory Status: FDA Classification: Tesamorelin (Egrifta) is FDA-approved for the treatment of lipodystrophy in HIV patients . However, use outside this specific indication is not approved and is intended exclusively for research. Research Use: Tesamorelin is available for in vitro and animal model scientific research to study its effects on visceral fat, body composition, and metabolism. Safety Considerations: Reported side effects are generally mild and include injection site redness, mild arthralgias, and in rare cases, headache or dizziness. Its use carries risks and is not recommended without medical supervision. Syntex Labs Quality Standards: Lab Grade: Purity ≥99% by HPLC-MS. QR Tracking: Complete batch traceability. Secure Batch Label: &amp;amp;amp;quot;Scratch to See&amp;amp;amp;quot; security system. 3rd Party Results: Access to Certificates of Analysis (COA) from accredited external laboratories.

Product Details

TESAMORELIN · 2 MG | Reduce la Grasa. Mejora tu Metabolismo.

TESAMORELIN · 2 MG | Reduce la Grasa. Mejora tu Metabolismo.

Build Your Stack

Frequently Asked Questions